Status:
COMPLETED
Quantifying Musical Performance After Treatment With Myobloc in Musician's Dystonia
Lead Sponsor:
Columbia University
Collaborating Sponsors:
Solstice Neurosciences
Conditions:
Focal Dystonia
Eligibility:
All Genders
25-69 years
Phase:
PHASE4
Brief Summary
This study uses a computerized method of musical instrument digital interface (MIDI) quantification of performance before and after treatment with botulinum toxin type B (Myobloc ®, Solstice Neuroscie...
Detailed Description
Dystonia represents a group of clinical disorders characterized by various combinations of sustained involuntary muscle contractions, abnormal postures and movements, tremors and pain. Dystonia can oc...
Eligibility Criteria
Inclusion
- Focal, task-specific dystonia clinically determined to be the result of a high level of musical skill and intensive performance history
Exclusion
- Neurological disorders other than dystonia
- Patients who are clinically depressed, demented or otherwise unable to perform appropriately or sit through 1 hour of testing
- Patients who have undergone pallidotomy, thalamotomy or deep brain stimulator implantations
- Patients who have who recently have taken medications with extrapyramidal or tremorogenic side effects
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00208091
Start Date
April 1 2003
End Date
May 1 2008
Last Update
May 9 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Neurological Institute, 710 W. 168th Street, NI-1112
New York, New York, United States, 10032